A new treatment option for poikiloderma of Civatte: 577 nm pro‐yellow laser.

Background: Although many laser systems have been used in the treatment for Poikiloderma of Civatte (POC), there is no standard treatment guideline. Objectives: We aimed to present our data on the efficacy and safety of single‐session pro‐yellow laser treatment for POC. Methods: The study included 14 patients treated with pro‐yellow laser (QuadroStarPRO YELLOW® Asclepion Laser Technologies, Germany) between 2017 and 2019. Treatment had been applied in two passes during the same session; a general pass with 22 j/cm2 over the whole lesion, then, one more pass only on the telangiectatic lesions with 18 j/cm2 fluence. They were evaluated based on their pictures taken before and 4 weeks after the treatment and scored by a 4‐item scoring in terms of the improvement (0:no change, 1:1%–25% mild, 2:26%–50% moderate, 3:51%–75% well, and 4:76%–100% excellent improvement). Results: The mean age of the patients (1 female, 13 males) was 59.64 ± 8.16 years. Five patients had Fitzpatrick‐2 and 9 patients had Fitzpatrick‐3 skin types. Six patients had mild, 8 patients had moderate improvement, one of them has been illustrated in Figure 1. Sixty‐minute mild erythema was the only adverse effect observed. Conclusions: We think that pro‐yellow laser is a good treatment option for POC treatment. Repeated sessions are required for the complete healing of the lesions, while one single session has proved to be deficient. We observed that it was a quite safe treatment option, especially for the neck region, which was inclined to scarring and atrophy development. [ABSTRACT FROM AUTHOR]